CN111448189A - 一种联芳基衍生物、其制备方法和在药学上的应用 - Google Patents

一种联芳基衍生物、其制备方法和在药学上的应用 Download PDF

Info

Publication number
CN111448189A
CN111448189A CN201980005084.9A CN201980005084A CN111448189A CN 111448189 A CN111448189 A CN 111448189A CN 201980005084 A CN201980005084 A CN 201980005084A CN 111448189 A CN111448189 A CN 111448189A
Authority
CN
China
Prior art keywords
good
deuterium
group
cyano
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980005084.9A
Other languages
English (en)
Inventor
杨飞
张永贤
应海燕
喻红平
陈椎
徐耀昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbisko Therapeutics Co Ltd
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of CN111448189A publication Critical patent/CN111448189A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

本发明涉及一种式(Ⅰ)结构具有对PD‑1/PD‑L1相互作用有抑制活性的联芳基衍生物、其制备方法和在药学上的应用。本发明系列化合物可广泛应用于制备预防和/或治疗由PD‑1/PD‑L1信号通路介导的癌症或肿瘤、免疫相关疾病及紊乱、传染性疾病、感染性疾病或代谢性疾病的药物,有望开发成新一代PD‑1/PD‑L1抑制剂。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201980005084.9A 2018-02-05 2019-01-29 一种联芳基衍生物、其制备方法和在药学上的应用 Pending CN111448189A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018101114135 2018-02-05
CN201810111413 2018-02-05
CN201810770644 2018-07-13
CN2018107706447 2018-07-13
PCT/CN2019/073594 WO2019149183A1 (zh) 2018-02-05 2019-01-29 一种联芳基衍生物、其制备方法和在药学上的应用

Publications (1)

Publication Number Publication Date
CN111448189A true CN111448189A (zh) 2020-07-24

Family

ID=67479570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980005084.9A Pending CN111448189A (zh) 2018-02-05 2019-01-29 一种联芳基衍生物、其制备方法和在药学上的应用

Country Status (13)

Country Link
US (1) US11459339B2 (zh)
EP (1) EP3750887A4 (zh)
JP (1) JP7033343B2 (zh)
KR (1) KR102534185B1 (zh)
CN (1) CN111448189A (zh)
AU (1) AU2019214089B2 (zh)
BR (1) BR112020014459A2 (zh)
CA (1) CA3088927C (zh)
MX (1) MX2020008205A (zh)
PH (1) PH12020551184A1 (zh)
SG (1) SG11202006409TA (zh)
TW (1) TWI828649B (zh)
WO (1) WO2019149183A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493469A (zh) * 2020-03-18 2021-10-12 成都倍特药业股份有限公司 可作为免疫调节剂的化合物、其制备方法和应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803651B (zh) 2016-06-27 2022-05-31 凯莫森特里克斯股份有限公司 免疫调节剂化合物
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
CA3070794A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. Immunomodulator compounds
CA3071951A1 (en) 2017-08-08 2019-02-14 Chemocentryx, Inc. Macrocyclic immunomodulators
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
US20210040118A1 (en) * 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CA3139526A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
US11485708B2 (en) 2019-06-20 2022-11-01 Chemocentryx, Inc. Compounds for treatment of PD-L1 diseases
EP3996711A4 (en) 2019-07-10 2023-08-16 ChemoCentryx, Inc. INDANES AS PD-L1 INHIBITORS
EP4001274A4 (en) * 2019-07-18 2023-07-26 Abbisko Therapeutics Co., Ltd. BIPHENYL DERIVATIVES FOR BLOCKING PD-1/PD-L1 INTERACTION, PROCESS FOR THEIR PREPARATION AND THEIR USE
CN114585359A (zh) 2019-10-16 2022-06-03 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
WO2021076688A1 (en) 2019-10-16 2021-04-22 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
US20230111910A1 (en) * 2020-01-21 2023-04-13 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof
CN113248492B (zh) * 2020-02-10 2022-11-08 上海海雁医药科技有限公司 杂环取代的含氮六元杂环衍生物及其制法与医药上的用途
CN114075123B (zh) * 2020-08-11 2023-06-06 中国人民解放军军事科学院军事医学研究院 苄胺类衍生物及其制备方法与用途
EP4159720A1 (en) * 2021-09-30 2023-04-05 Recepton Spolka z Ograniczona Odpowiedzialnoscia Nonsymmetric substituted 1,1'-biphenyl derivatives and uses thereof
WO2023169373A1 (zh) * 2022-03-07 2023-09-14 上海和誉生物医药科技有限公司 一种全对称联苯基衍生物及其制备方法和应用
CN117343006A (zh) * 2023-10-08 2024-01-05 河南科技大学 一种arb-272572的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044783A1 (en) * 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014315457B2 (en) * 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2916874T3 (es) * 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
HUE060256T2 (hu) * 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
CN107573332B (zh) * 2016-07-05 2022-04-19 广州再极医药科技有限公司 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用
CN109195602B (zh) * 2016-08-03 2022-01-07 上海齐鲁制药研究中心有限公司 用作免疫调节剂的对称或半对称化合物
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044783A1 (en) * 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119224A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493469A (zh) * 2020-03-18 2021-10-12 成都倍特药业股份有限公司 可作为免疫调节剂的化合物、其制备方法和应用

Also Published As

Publication number Publication date
JP7033343B2 (ja) 2022-03-10
BR112020014459A2 (pt) 2020-12-15
KR102534185B1 (ko) 2023-05-18
CA3088927A1 (en) 2019-08-08
CA3088927C (en) 2023-03-21
JP2021512878A (ja) 2021-05-20
SG11202006409TA (en) 2020-08-28
EP3750887A1 (en) 2020-12-16
RU2768830C2 (ru) 2022-03-24
AU2019214089B2 (en) 2021-02-11
RU2020127950A3 (zh) 2022-03-11
EP3750887A4 (en) 2021-10-20
US11459339B2 (en) 2022-10-04
US20210032270A1 (en) 2021-02-04
RU2020127950A (ru) 2022-03-11
WO2019149183A1 (zh) 2019-08-08
KR20200100717A (ko) 2020-08-26
MX2020008205A (es) 2020-09-18
PH12020551184A1 (en) 2021-05-10
AU2019214089A1 (en) 2020-07-09
TWI828649B (zh) 2024-01-11
TW201934544A (zh) 2019-09-01

Similar Documents

Publication Publication Date Title
CN111448189A (zh) 一种联芳基衍生物、其制备方法和在药学上的应用
US10202365B2 (en) 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN103068384B (zh) 表现出抗癌和抗增生活性的环丙基二甲酰胺以及类似物
EP3269370A1 (en) Novel condensed pyrimidine compound or salt thereof
BR112018008877B1 (pt) Compostos inibidores de ret, composição farmacêutica e usos dos referidos compostos
EP3705480B1 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
TWI781607B (zh) 一種免疫抑制劑、其製備方法和應用
JP2023145548A (ja) Ｃｄ７３阻害剤、その製造方法と応用
CA3069602A1 (en) Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof
WO2021008491A1 (zh) 一种阻断pd-1/pd-l1相互作用的联苯基衍生物及其制备方法和应用
TWI676625B (zh) 磺醯胺類衍生物、其製備方法及其在醫藥上的用途
KR102606167B1 (ko) 불소 함유 치환 벤조티오펜 화합물, 그의 약학적 조성물 및 응용
WO2023169373A1 (zh) 一种全对称联苯基衍生物及其制备方法和应用
CN114502556B (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
RU2768830C9 (ru) Производное биарила, метод его получения и его фармацевтическое применение
CN116768889A (zh) 一种新型cdk9激酶抑制剂及其制备方法和应用
CN109400517A (zh) 1-甲基-色氨酸类化合物及其制备方法和用途
JP2008120699A (ja) 新規ピリジニウム誘導体および医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023971

Country of ref document: HK